Why Skills-First Leadership Is Replacing the Ivy League Playbook in the C-Suite
05/23/2025
No Comments
The old prestige pyramid—where Ivy League degrees and blue-chip consulting backgrounds paved the way to the CEO seat—is cracking.
June 21, 2023: On Tuesday, Eli Lilly said it slapped a $2.4 billion contract to develop Dice Therapeutics to stock up its medicine portfolio for immune-related diseases.
Eli Lilly will be spending $48 per share in cash to buy Dice, which shows around a 40% bonus to where the San Francisco-based company’s shares closed on Friday. The transaction is anticipated to close in the third quarter of this year.
Eli Lilly’s stock price increased by over 1% in early morning trading. Dice Therapeutics’ share cost increased over 37% to just under the purchase price.
“In combination with its novel technology and expertise in drug discovery, DICE’s talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating immune diseases,” stated Patrik Jonsson, Eli Lilly executive vice president, in a press release.
Dice is a biopharmaceutical company that uses a proprietary technology platform to develop reenergized oral therapeutic drugs for autoimmune diseases, in which the body’s immune system erroneously attacks a person’s cells instead of protecting them.
Autoimmune diseases can induce pain, fatigue, dizziness, depression, and rashes, among other symptoms.
Over 100 known autoimmune diseases include lupus, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
Dice’s lead drug is in a midstage test for an immune-related skin condition called psoriasis.
Eli Lilly’s immunology portfolio includes drugs such as Taltz, which treats plaque psoriasis, and Olumiant, a therapy for rheumatoid arthritis. The previous year, Taltz raked in $2.48 billion, while Olumiant generated $830.5 million in sales.
The old prestige pyramid—where Ivy League degrees and blue-chip consulting backgrounds paved the way to the CEO seat—is cracking.
Loud leaders once ruled the boardroom. Charisma was currency. Big talk drove big valuations.
But the CEOs who make history in downturns aren’t the ones with the deepest cuts
Companies invest millions in leadership development, yet many of their best executives leave within a few years. Why?
The most successful business leaders don’t just identify gaps in the market; they anticipate future needs before anyone else.
With technological advancements, shifting consumer expectations, and global interconnectedness, the role of business leaders
Maushum Basu is a visionary leader who inspires his team with a clear, compelling purpose. Unafraid to take calculated risks, he understands that growth often stems from change and innovation. His deep commitment to both Airia Brands, Inc.
When speaking with Martin Paquette, one thing is immediately apparent: he’s honest. His transparency is refreshing. While many shy away from such vulnerability, Paquette sees it as a force to reckon with. The incredible emotional intelligence speaks to years of looking within—it’s also what allows him to acknowledge his mistakes gracefully and use them as opportunities to innovate.
Marina Charriere, CEO of Star Drug Testing Services, Star Drug Testing Services (Windsor Park), and First Defence Face Masks go hand in hand. Star is a drug and alcohol testing facility, and First D F M is a face mask company.
Lejjy Gafour, CEO, CULT Food Science Corp. Lejjy is a self-taught entrepreneur and experienced company operator who made his start creating opportunities at the young age of 14, and he has been working, leading, and building businesses ever since.
Leave us a message
Subscribe
Fill the form our team will contact you
Advertise with us
Fill the form our team will contact you
